entrinsic bioscience Strengthens Leadership Team with Appointment of Mario Wanderley as Chief Financial Officer and Accelerates Product Development with New Research Facility

UF startup and UF Innovate | Sid Martin Biotech resident client entrinsic bioscience (EBS), a company pioneering a next-generation protein modulation technology, announced the appointment of Mario Wanderley
as Chief Financial Officer. Mr. Wanderley brings 23 years of financial, operational, and strategic expertise to EBS, with significant experience in the medical device, technology, software, telecommunications, and manufacturing sectors.

“The addition of Mario as Chief Financial Officer strengthens our leadership team and will help us accelerate the development and commercialization of our platform as we expand our footprint,” said Stephen Gatto, CEO of entrinsic bioscience. “Mario’s capital markets expertise, as well as his extensive transactional and operational background, will be invaluable as we continue to drive our business strategy forward.”

Learn more about entrinsic bioscience Strengthens Leadership Team with Appointment of Mario Wanderley as Chief Financial Officer and Accelerates Product Development with New Research Facility.